ChartMill · Aug 19, 2026
CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup
CG Oncology (CGON) earns perfect 10/10 technical and setup ratings, near highs with defined breakout entry—top breakout setup stock.
CG
NASDAQ · CGON
CG Oncology, Inc. Common stock
Healthcare · Biotechnology
$72.55
Up+$0.46 (+0.63%)
Updated Sep 16, 2026, 3:13 PM
SID Score
5.9/10
Composite research score
Smart Money
61/100
Neutral
- Market cap
- 3.12B
- P/E ratio
- -29.65
- Dividend yield
- 0.00%
- 52-week range
- $33.80 – $80.97
- Volume
- 1.04M
- Avg. volume
- 990.79K
Price performance
CGON price history
1M range · 20 trading sessions · Daily adjusted prices
CGON closed at $72.55 after 20 trading sessions, down 4.90% for the selected period.
- Last close
- $72.55
- Period change
- -4.90%
- Period low
- $71.96
- Period high
- $80.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $74.13 | $74.13 | $72.4781 | $72.55 | 1.04M |
| Sep 14, 2026 | $72.30 | $74.67 | $71.78 | $73.79 | 829.92K |
| Sep 11, 2026 | $72.82 | $75.00 | $71.525 | $72.35 | 759.84K |
| Sep 10, 2026 | $70.91 | $72.58 | $70.00 | $72.00 | 657.93K |
| Sep 9, 2026 | $73.04 | $74.8499 | $70.9001 | $71.96 | 707.94K |
| Sep 8, 2026 | $73.23 | $74.60 | $72.25 | $73.40 | 550.84K |
| Sep 4, 2026 | $73.02 | $74.875 | $72.87 | $74.67 | 282.52K |
| Sep 3, 2026 | $74.94 | $75.0244 | $73.69 | $74.33 | 359.67K |
| Sep 2, 2026 | $76.84 | $79.23 | $73.89 | $74.59 | 663.89K |
| Sep 1, 2026 | $74.74 | $76.235 | $74.195 | $75.86 | 876.13K |
| Aug 31, 2026 | $74.09 | $76.14 | $72.12 | $75.16 | 840.74K |
| Aug 28, 2026 | $78.15 | $78.155 | $73.93 | $74.34 | 612.57K |
| Aug 27, 2026 | $78.01 | $79.40 | $77.63 | $79.01 | 328.93K |
| Aug 26, 2026 | $78.29 | $78.94 | $76.87 | $78.42 | 507.81K |
| Aug 25, 2026 | $79.00 | $80.07 | $78.10 | $78.95 | 736.17K |
| Aug 24, 2026 | $79.44 | $79.89 | $77.51 | $78.23 | 1.16M |
| Aug 21, 2026 | $78.69 | $79.89 | $77.38 | $79.81 | 701.89K |
| Aug 20, 2026 | $79.50 | $79.7075 | $77.17 | $77.61 | 668.03K |
| Aug 19, 2026 | $77.80 | $80.97 | $77.00 | $80.68 | 845.88K |
| Aug 18, 2026 | $75.83 | $77.50 | $75.31 | $76.29 | 562.5K |
Latest CGON news
The latest Smart Investors Daily articles mentioning CGON.
Stock researchCompany · Overview
CGON research
Overview
Company profile and research snapshot.
Company profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $69.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| May 19, 2026 | Wolfe Research | Peer Perform | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 27, 2026
What Analysts Are Saying About CG Oncology Stock
Benzinga · Feb 27, 2026
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
Benzinga · Feb 27, 2026
CG Oncology Q4 Earnings Report: What Investors Need to Know
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
